Galmed Pharmaceuticals Ltd.
GLMD
Price:
$2.75
Market Cap:
$4.56M
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research a...[Read more]
Industry
Biotechnology
IPO Date
2014-03-13
Stock Exchange
NASDAQ
Ticker
GLMD
PE Ratio
[0.04]
ROE
[-44.49%]
Current Ratio
[7.03]
Dividend Yield
[0%]
Enterprise Value
[-5167277.00]
Dividend History
The ROE as of November 2024 (TTM) for Galmed Pharmaceuticals Ltd. (GLMD) is -44.49%
According to Galmed Pharmaceuticals Ltd.’s latest financial reports and current stock price. The company's current ROE is -44.49%. This represents a change of 300.84% compared to the average of -11.10% of the last 4 quarters.
Galmed Pharmaceuticals Ltd. (GLMD) Historical ROE (quarterly & annually)
How has GLMD ROE performed in the past?
The mean historical ROE of Galmed Pharmaceuticals Ltd. over the last ten years is -70.24%. The current -44.49% ROE has changed -36.66% with respect to the historical average. Over the past ten years (40 quarters), GLMD's ROE was at its highest in in the September 2018 quarter at -1.06%. The ROE was at its lowest in in the December 2016 quarter at -43.58%.
Average
-70.24%
Median
-56.17%
Minimum
-153.07%
Maximum
-11.21%
Galmed Pharmaceuticals Ltd. (GLMD) ROE by Quarter and Year
Discovering the peaks and valleys of Galmed Pharmaceuticals Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 210.49%
Maximum Annual ROE = -11.21%
Minimum Annual Increase = -103.23%
Minimum Annual ROE = -153.07%
| Year | ROE | Change |
|---|---|---|
| 2023 | -49.80% | -64.00% |
| 2022 | -138.35% | 32.07% |
| 2021 | -104.76% | 67.53% |
| 2020 | -62.53% | 135.59% |
| 2019 | -26.54% | 136.70% |
| 2018 | -11.21% | -85.60% |
| 2017 | -77.87% | -49.13% |
| 2016 | -153.07% | 210.49% |
| 2015 | -49.30% | 70.10% |
| 2014 | -28.98% | -103.23% |
Galmed Pharmaceuticals Ltd. (GLMD) Average ROE
How has GLMD ROE performed in the past?
The current ROE of Galmed Pharmaceuticals Ltd. (GLMD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-97.64%
5-year avg
-76.40%
10-year avg
-70.24%
Galmed Pharmaceuticals Ltd. (GLMD) ROE vs. Peers
How is GLMD’s ROE compared to its peers?
Galmed Pharmaceuticals Ltd.’s ROE is less than Affimed N.V. (0%), greater than Abeona Therapeutics Inc. (-193.85%), greater than Akebia Therapeutics, Inc. (-227.38%), less than Kodiak Sciences Inc. (129.56%), greater than Mereo BioPharma Group plc (-84.52%), greater than Adverum Biotechnologies, Inc. (-69.11%), greater than Adaptimmune Therapeutics plc (-65.14%), greater than Pieris Pharmaceuticals, Inc. (-74.84%), greater than PDS Biotechnology Corporation (-76.24%), greater than Leap Therapeutics, Inc. (-139.57%), greater than Fortress Biotech, Inc. (-116.24%), greater than Mustang Bio, Inc. (-240.30%), less than Achilles Therapeutics plc (429.53%), greater than Aptose Biosciences Inc. (-54.57%), less than Fortress Biotech, Inc. (1.03%), greater than null (-240.30%),
| Company | ROE | Market cap |
|---|---|---|
| 0% | $39.90M | |
| -193.85% | $259.96M | |
| -227.38% | $410.18M | |
| 129.56% | $325.74M | |
| -84.52% | $575.61M | |
| -69.11% | $125.65M | |
| -65.14% | $176.64M | |
| -74.84% | $22.15M | |
| -76.24% | $78.19M | |
| -139.57% | $97.71M | |
| -116.24% | $44.44M | |
| -240.30% | $9.63M | |
| 429.53% | $43.57M | |
| -54.57% | $3.71M | |
| 1.03% | $42.11M | |
| -240.30% | $0 |
Build a custom stock screener for Galmed Pharmaceuticals Ltd. (GLMD) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Galmed Pharmaceuticals Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Galmed Pharmaceuticals Ltd. (GLMD) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Galmed Pharmaceuticals Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Galmed Pharmaceuticals Ltd.'s ROE?
How is the ROE calculated for Galmed Pharmaceuticals Ltd. (GLMD)?
What is the highest ROE for Galmed Pharmaceuticals Ltd. (GLMD)?
What is the 3-year average ROE for Galmed Pharmaceuticals Ltd. (GLMD)?
What is the 5-year average ROE for Galmed Pharmaceuticals Ltd. (GLMD)?
How does the current ROE for Galmed Pharmaceuticals Ltd. (GLMD) compare to its historical average?